Glykos announced today that it has entered into a collaboration with Sanofi-Aventis Recherche & Développement, The French R&D affiliate of Sanofi, to evaluate Glykos’ proprietary Antibody-Drug Conjugate (ADC) technologies in the development of next generation ADCs.
Under the agreement, Glykos will provide its proprietary hydrophilic linker technology to Sanofi. This arrangement will enable Sanofi to use Glykos’ hydrophilic linkers in conjunction with Sanofi proprietary payloads and antibodies in order to generate and evaluate ADC physicochemistry properties, pharmacokinetics, efficacy and safety.
Juhani Saarinen, CEO and co-founder of Glykos, said: “Glykos is pleased to collaborate with Sanofi, a leader in its field, in developing improved ADCs. By combining Sanofi’s expertise in anti-tumor antibodies and cytotoxic payloads with our novel linker technology we are aiming to create next-generation ADCs with improved properties.”
About Glykos
Glykos, based in Helsinki, Finland, discovers and develops products and technologies based on bioactive glycans. Glykos’ work is focused on three areas: ADC technologies, novel glycan based oncology targets and antibodies (cancer and cancer stem cell targets), and stem cell glycomics. Glykos’ antibody-drug conjugation technologies include novel hydrophilic linkers and proprietary hydrophilic payloads that allow high drug-to-antibody ratios.
Contacts Glykos: Juhani Saarinen, CEO Tel: +35 85 05 48 42 43 Juhani.saarinen@glykos.fi
Help employers find you! Check out all the jobs and post your resume.
